🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🏥TNT with TAS-102 in LA rectal cancer eClinicalMedicine – The Lancet Discovery Science ➡️Long course CRT with TAS-102 > 2 cycles TA-102 plus Oxa > surgery > 4 cycles Capeox ✅pCR: 32%, MPR: 52% 👉thelancet.com/journals/eclin… #cancer #oncology #MedX #rectal #GI OncoAlert Dr Joseph McCollom DO

Food insecurity is linked to increased all-cause mortality among cancer survivors, highlighting the need for routine screening and integration of food assistance into cancer care. ja.ma/3TezRP7

Neoadjuvant cobolimab & dostarlimab followed by surgery & adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in high-risk, resectable melanoma. Research presented at #ASCO25 by Meghan Mooradian of MassGeneral News. #skcsm #melsm shorturl.at/QpS8W

Looking for the latest breast cancer research, conference news, and guideline updates? Sign up for the Grand Roundup, our curated and specialized bi-weekly newsletter on clinical topics that matter most to you. bit.ly/4jYkuFw

Mosunetuzumab plus polatuzumab vedotin improved outcomes over chemoimmunotherapy in patients with transplant-ineligible, relapsed/refractory LBCL, according to research presented at #18ICML by Jason Westin, MD FACP FASCO of MD Anderson Cancer Center. #lymsm shorturl.at/Y5ITb

The combination of cabozantinib and atezolizumab appeared more effective than switching ARPI therapy in a phase 3 trial of patients with #mCRPC and extrapelvic soft-tissue metastases who had disease progression on an ARPI. Published in The Lancet Oncology. bit.ly/44hmD9t

Ropeginterferon alfa-2b proved more effective than anagrelide in a phase 3 trial of patients with high-risk essential #thrombocythemia who were resistant or intolerant to hydroxyurea. Presented at the European Hematology Association conference #EHA2025, covered by CancerTherapyAdvisor.

Ropeginterferon alfa-2b proved more effective than anagrelide in a phase 3 trial of patients with high-risk essential #thrombocythemia who were resistant or intolerant to hydroxyurea. Presented at European Hematology Association #EHA2025. bit.ly/44rK9Sh

Satricabtagene autoleucel (satri-cel) can improve outcomes when compared to standard therapy in patients with previously treated, advanced gastric or #GEJcancer. Presented at #ASCO25. bit.ly/4lkQK6y #gicsm

Looking for a curated list of the top news and updates on lung cancer? Sign up for the Grand Roundup newsletter, delivered to your inbox bi-weekly. bit.ly/4jYkuFw

PTCy plus cyclosporine is more effective than standard #GVHD prophylaxis in patients undergoing matched sibling PBSCT. Presented at European Hematology Association #EHA2025. bit.ly/4llNgkg

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with R/R #multipleMyeloma. Presented at European Hematology Association #EHA2025. bit.ly/3G69Gr0 #mmsm

The combination of ibrutinib and rituximab can improve outcomes when compared to rituximab alone in patients with previously untreated FL who are ineligible for chemoimmunotherapy, according data presented at #18ICML. bit.ly/44b653Z #lymsm #follicularlymphoma

New research has revealed age-specific trends in #breastcancer incidence among women who are 65 years of age and older. Published in JAMA Network Open. bit.ly/3GqKITe #bcsm

NIVO + IPI vs NIVO for MSI-H/dMMR mCRC: Health-related quality of life analysis 🔎CheckMate 8HW 👉mPFS clearly improved 👉 HRQoL, less symptoms 🧐 Supports use of Nivo IPI as 1st line treatment in MSI CRC #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

One of my 🔝 abstracts from ESMO - Eur. Oncology #ESMOGI25 #TALENTACE in #IntStage #HCC AtezoBev +TACE vs TACE (China) TACE-PFS and PFS benefit 😉I favour PFS over TACE-PFS ✅Supports EMERALD-1 and LEAP-012 🤩Systemic stays for IntStage HCC Lorenza Rimassa🔝🔝discussion #ESMOAmbassadors

#Cancer patients receiving ICI therapy may experience more severe #toxicity and have a greater risk of death if they have recently used PPIs. Published in Journal of the @NCCN. bit.ly/4lS4pCH #MedOnc

Waiting about 9 months or more to rechallenge patients with amivantamab after disease progression on prior EGFR inhibitor therapy can improve outcomes in patients with advanced CRC, according to research presented at #ESMOGI25. #gicsm shorturl.at/9j5kz

Sign up today for our bi-weekly email covering emerging research, conference news, and guideline updates on general oncology, breast cancer and lung cancer: bit.ly/4jYkuFw

Roughly half of all #cancerdeaths worldwide are attributable to modifiable risk factors, according to The Cancer Atlas, a report released by American Cancer Society and the IARC. bit.ly/4l77VJb